Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Mirjana Zeremski"'
Autor:
Jorge E. Cortes, Geoffrey Chan, Ashleigh O'Connell, Mirjana Zeremski, A. Douglas Laird, M. Naveed Shaik, Weidong Wendy Ma, Hagop M. Kantarjian, James McCloskey, Jeffrey Lancet, Mark A. Schroeder, Vivian G. Oehler, Wendy Stock, Daniel A. Pollyea, Michael R. Savona
Purpose: This open-label, multicenter, dose-finding, phase Ib study (NCT01546038) evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of the novel Hedgehog pathway Smoothened inhibitor glasdegib (PF-04449913) in patients (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fe667682407264cca4df8cd19f3fd28
https://doi.org/10.1158/1078-0432.c.6525722.v1
https://doi.org/10.1158/1078-0432.c.6525722.v1
Autor:
Jorge E. Cortes, Geoffrey Chan, Ashleigh O'Connell, Mirjana Zeremski, A. Douglas Laird, M. Naveed Shaik, Weidong Wendy Ma, Hagop M. Kantarjian, James McCloskey, Jeffrey Lancet, Mark A. Schroeder, Vivian G. Oehler, Wendy Stock, Daniel A. Pollyea, Michael R. Savona
Additional Methods: MTD determination; Biomarker analyzed Supplementary Table S1. Patient disposition by treatment group Supplementary Table S2. Treatment-related AEs reported in >10% of patients in arm A Supplementary Table S3. Treatment-related AEs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::030fa3fc24f2ed0aaede5e6bfe9fd078
https://doi.org/10.1158/1078-0432.22464449
https://doi.org/10.1158/1078-0432.22464449
Autor:
B. Douglas Smith, Mirjana Zeremski, Walter Fiedler, Pau Montesinos, Michael Heuser, Mikkael A. Sekeres, Cristina Papayannidis, Geoffrey Chan, Caroline J. Hoang, Akil Merchant, Ashleigh O'Connell, Jorge E. Cortes, José Antonio Pérez-Simón, Weidong Wendy Ma, Thomas O’Brien, Brian Leber
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Annals of Hematology
instname
Annals of Hematology
This analysis from the phase II BRIGHT AML 1003 trial reports the long-term efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf99cb1bd4b9373e2b9e23f253f13597
https://doi.org/10.1007/s00277-021-04465-4
https://doi.org/10.1007/s00277-021-04465-4
Autor:
Michael Heuser, Mikkael A. Sekeres, José A. Pérez-Simón, Weidong Wendy Ma, Mirjana Zeremski, Thomas O’Brien, Caroline J. Hoang, Akil Merchant, Cristina Papayannidis, Jorge E. Cortes, Walter Fiedler, Brian Leber, Ashleigh O'Connell, Pau Montesinos, B. Douglas Smith, Geoffrey Chan
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Ann Hematol
instname
Ann Hematol
This analysis from the phase II BRIGHT AML 1003 trial reports the long-term efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df25aca21278bc88b7787e214a6153f9
https://link.springer.com/content/pdf/10.1007/s00277-021-04545-5.pdf
https://link.springer.com/content/pdf/10.1007/s00277-021-04545-5.pdf
Autor:
Eunice S. Wang, Naveed Shaik, A. Douglas Laird, Jorge E. Cortes, Akil Merchant, Weidong Wendy Ma, Daniel J. DeAngelo, Tadeusz Robak, Mirjana Zeremski, Mikkael A. Sekeres, B. Douglas Smith, Ashleigh O'Connell, Martha Arellano, Geoffrey Chan, Daniel A. Pollyea, Vivian G. Oehler, Mark A. Schroeder
Publikováno v:
American Journal of Hematology
Glasdegib is a Hedgehog pathway inhibitor. This ongoing, open‐label, phase 2 study ({"type":"clinical-trial","attrs":{"text":"NCT01546038","term_id":"NCT01546038"}}NCT01546038) evaluated glasdegib plus cytarabine/daunorubicin in patients with untre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66d7b3d84f6411556fd30ad7ef852ef4
http://europepmc.org/articles/PMC6221102
http://europepmc.org/articles/PMC6221102
Autor:
Mirjana Zeremski, Eunice S. Wang, Weidong Ma, Arthur Kudla, Jürgen Krauter, Emmanuel Gyan, Michael W. Schuster, Magalie Joris, Amit Verma, Johan Maertens, Amer M. Zeidan, Mikkael A. Sekeres, Geoffrey Chan, Tibor Kovacsovics, Paresh Vyas
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S191-S192
Context Glasdegib + azacitidine (AZA) showed promising remission rates and overall survival with a generally well-tolerated and manageable safety profile in an analysis of BRIGHT MDS & AML 1012 ( NCT02367456 ) in patients with higher-risk myelodyspla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32576801f9466af7f60b094daf82f748
https://doi.org/10.1016/s2152-2650(20)30733-3
https://doi.org/10.1016/s2152-2650(20)30733-3
Autor:
Hironobu Minami, Naveed Shaik, Catriona Jamieson, Norio Komatsu, Ellen K. Ritchie, Mark L. Heaney, Michael W. Deininger, Moshe Talpaz, Christine DiRienzo, Mirjana Zeremski, Yun Su, Tetsuzo Tauchi, Ruben A. Mesa, Aaron T. Gerds, Geoffrey Chan, Xiaoxi Zhang
Publikováno v:
Leuk Res
Glasdegib is a potent and selective oral inhibitor of the Hedgehog pathway. We report data from the single-arm, lead-in cohort of an open-label phase 1b/2 trial of glasdegib in patients with primary/secondary myelofibrosis (MF) previously treated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02252aa9cee578067d1ba41cb89fa30c
https://europepmc.org/articles/PMC8148985/
https://europepmc.org/articles/PMC8148985/
Autor:
Emmanuel Gyan, Mirjana Zeremski, Tibor Kovacsovics, Art Kudla, Eunice S. Wang, Magalie Joris, Paresh Vyas, Johan Maertens, Wendy Ma, Amer M. Zeidan, Michael W. Schuster, Geoffrey Chan, Mikkael A. Sekeres, Jürgen Krauter, Amit Verma
Publikováno v:
Journal of Clinical Oncology. 38:7526-7526
7526 Background: Glasdegib, an oral inhibitor of the Hedgehog signaling pathway, is approved in the USA in combination with low-dose cytarabine to treat pts with newly diagnosed AML unable to receive intensive chemotherapy due to comorbidities or age
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7a547131b74295484ab7e25ab76358f
https://doi.org/10.1200/jco.2020.38.15_suppl.7526
https://doi.org/10.1200/jco.2020.38.15_suppl.7526
Autor:
M. Heuser, W. Fiedler, Geoffrey Chan, C. Papayannidis, Caroline J. Hoang, Akil Merchant, J.A. Pérez-Simón, Jorge E. Cortes, Mirjana Zeremski, Ashleigh O'Connell, B. Leber, Pau Montesinos, Mikkael A. Sekeres, W.W. Ma
Publikováno v:
HemaSphere. 3:464-465
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f037b2d8ab0e0e0b6d444d73f20c821
https://doi.org/10.1097/01.hs9.0000562412.43628.df
https://doi.org/10.1097/01.hs9.0000562412.43628.df
Autor:
Ashleigh O'Connell, Mirjana Zeremski, Caroline J. Hoang, G. Schiller, A. Oriol, Mikkael A. Sekeres, A. Candoni, Jorge E. Cortes, Michael Heuser, B.D. Smith, C. Jamieson, Geoffrey Chan, C. Papayannidis, Pau Montesinos, W.W. Ma
Publikováno v:
HemaSphere. 3:97-98
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b62ef8e4554caf0cb4756dc311b36c1c
https://doi.org/10.1097/01.hs9.0000559380.25053.cc
https://doi.org/10.1097/01.hs9.0000559380.25053.cc